Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Net Income Growth (3y) (2012 - 2026)

Analysis

Charles River Laboratories International (CRL) Net Income Growth (3y) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn -6.41%
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn 25.73%
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn -1.49%
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn -26.15%
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -34.42%
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn 35.41%
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn 45.04%
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -19.47%
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 27, 2026 -26.15%
Mar 28, 2026 -28.91%
Dec 27, 2025 -51.26%
Sep 27, 2025 -17.13%
Jun 28, 2025 -21.91%
Mar 29, 2025 -35.23%
Dec 28, 2024 -52.24%
Sep 28, 2024 -12.56%
Jun 29, 2024 1.59%
Mar 30, 2024 5.22%
Dec 30, 2023 9.43%
Sep 30, 2023 -4.98%
Jul 1, 2023 13.69%
Apr 1, 2023 26.93%
Dec 31, 2022 32.93%
Sep 24, 2022 9.89%
Jun 25, 2022 35.68%
Mar 26, 2022 19.58%
Dec 25, 2021 32.44%
Sep 25, 2021 19.97%